Description: PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Home Page: www.polypeptide.com
Dammstrasse 19
Zug,
6300
Switzerland
Phone:
41 41 723 20 34
Officers
| Name | Title |
|---|---|
| Dr. Raymond De Vre Ph.D. | Chief Exec. Officer |
| Mr. Jan Fuhr Miller | Chief Financial Officer |
| Mr. Daniel Lasanow | Director of Global Operations |
| Mr. Michael Staheli | Head of Investor Relations & Corp. Communications |
| Ms. Christina Del Vecchio | Gen. Counsel & Corp. Sec. |
| Mr. Neil James Thompson | Director of Global Sales & Marketing |
| Monika Casanova | Chief HR Officer |
| Mr. Jan Christensen | Exec. Officer |
Exchange: SW
Country: CH : Switzerland
Currency: Swiss Franc (CHF)
| Forward PE: | 22.6757 |
|---|---|
| Trailing PE: | 28.3093 |
| Price-to-Book MRQ: | 1.9024 |
| Price-to-Sales TTM: | 2.822 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1156 |